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Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for malignancies
such as multiple myeloma (MM) and lymphomas. Various changes in the ﬁeld over the past decade, including
the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and
lymphoma, and the addition of new stem cell mobilization techniques, have led to the need to reassess
current stem cell mobilization strategies. Mobilization failures with traditional strategies are common and
result in delays in treatment and increased cost and resource utilization. Recently, plerixafor-containing
strategies have been shown to signiﬁcantly reduce mobilization failure rates, but the ideal method to
maximize stem cell yields and minimize costs associated with collection has not yet been determined. A
panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell
mobilization and transplantation and to devise guidelines to optimize mobilization strategies. Herein is a
summary of their discussion and consensus.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous hematopoietic stem cell transplantation
(aHSCT) is used routinely in the treatment of multiple
myeloma (MM) [1-8], non-Hodgkin lymphoma (NHL), and
Hodgkin lymphoma [9-11]. For patients with MM and
relapsed chemosensitive NHL, aHSCT leads to improved
progression-free survival and overall survival. Patients with
MM achieve higher rates of complete remission with aHSCT
than with chemotherapy alone.
Nearly 10,000 aHSCTs are performed in the United States
annually, virtually all of them supported by peripheral blooddgments on page 303.
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13.10.013stem cells (PBSCs) [12]. There are 2 general approaches
to stem cell collection: cytokinemobilization using cytokines
such as ﬁlgrastim (granulocyte-colony stimulating factor
[G-CSF]), pegﬁlgrastim, or sargramostim (granulocyte
macrophage-colony stimulating factor [GM-CSF]) alone or in
combination, and chemomobilization (CM) using chemo-
therapy followed by cytokine administration. The published
literature on these mobilization approaches is vast, but the
relative efﬁcacy, safety, and costs of each remain unclear
owing to the paucity of high-quality randomized controlled
trials comparing various mobilization strategies [13].Historical Approaches to Stem Cell Mobilization
Following the observation that chemotherapy adminis-
tration resulted in a temporary increase in circulation of
stem cells during hematopoietic recovery, early stem cell
mobilization techniques relied on chemotherapy aloneTransplantation.
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cytokines further improved our ability to mobilize and
collect PBSCs [16,17]. Currently, both steady-state and
chemotherapy-based mobilization rely on the use of myeloid
growth factors for the release of stem cells into the periph-
eral blood (PB). G-CSF, the most potent of the commercially
available myeloid growth factors [18], works by inducing the
release of various proteases into the marrow, which then
cleave adhesion molecules such as SDF-1, releasing he-
matopoietic stem cells into the PB [19]. The use of chemo-
therapy before administration of high-dose myeloid growth
factors generally produces higher stem cell yields [20-25],
and in theory may reduce tumor contamination of the stem
cell product, although data to conﬁrm this are lacking.Mobilization Beyond Myeloid Growth Factors
The biology of hematopoietic stem cell mobilization with
agents other than G-CSF has been reviewed recently [26].
The novel stem cell mobilizing agent plerixafor has recently
provided another mobilization option for the transplantation
community. In 2008, plerixafor was approved for use in the
United States in combinationwith G-CSF for the mobilization
of hematopoietic stem cells in patients with NHL and MM
undergoing high-dose chemotherapy followed by autolo-
gous stem cell rescue. Plerixafor is a reversible CXCR4
antagonist that allows the release of stem cells from the
marrow by disrupting the interaction of CXCR4 with SDF-1.
Administration of plerixafor in conjunction with G-CSF
augments mobilization of CD34þ cells into the PB, with a
peak effect occurring 4-9 hours after administration but a
much longer sustained effect, allowing for later initiation of
apheresis [27].
The stem cell population mobilized by the combination of
plerixafor and G-CSF differs from that mobilized by G-CSF
alone. Plerixafor-mobilized PBSCs and/or apheresis products
have higher proportions of cells in growth phase [28],
primitive CD34þCD38 progenitor cells [29], B and T lym-
phocytes [30-32], dendritic cells [33], and natural killer cells
[30,32]. Stem cells mobilized by plerixafor also have
increased expression of VLA-4 and CXCR4 [28], as well as of
genes that promote cell adhesion, cell motility, the cell cycle,
and antiapoptosis [34]. These characteristics suggest that
plerixafor-mobilized cell products may have greater capacity
to repopulate the marrow and reconstitute the immune
system compared with grafts mobilized by G-CSF alone.
These properties have been conﬁrmed in mouse and primate
models [35,36].
Shortly after the December 15, 2008, approval of pler-
ixafor in the United States, guidelines and recommenda-
tions were published on the current status of stem cell
collection and the role of plerixafor in patients with MM
[37,38]. The consensus in these publications was that
plerixafor, along with novel agents for treating MM, would
change the standards of practice for aHSCT over the coming
decade. Although the use of plerixafor for stem cell mobi-
lization has become increasingly common since those ﬁrst
publications, the transplantation community at large has
yet to determine its optimal role in mobilization not only in
patients with MM and NHL, but also in patients with
Hodgkin lymphoma and solid tumors. In October 2011, a
panel of experts in stem cell mobilization and aHSCT was
convened to review recently published mobilization and
collection data and update the guidelines for maximizing
mobilization outcomes.Recommendations for Stem Cell Collection
Minimum and Target Cell Doses for aHSCT
The correlation between the number of stem cells infused
for aHSCT and engraftment kinetics is well established.
Administration of CD34þ cell doses <1.5-2.5  106/kg leads
to delayed neutrophil recovery [39-43], and administration
of doses<1106/kg has been associated with increased RBC
transfusion requirements and even permanent loss of
engraftment [42]. Signiﬁcant delays in platelet recovery also
have been seen with infusion of <1.5-2.5  106 CD34þ cells/
kg [24,41-44], whereas infusion of >3-5  106 cells/kg is
associated with earlier neutrophil and platelet engraftment
[39,41,45].
A recent post hoc analysis of the utility and added beneﬁt
of higher stem cell doses in patients undergoing aHSCT
demonstrated that CD34þ cell doses >6  106/kg were asso-
ciated with improved long-term platelet recovery and
reduced blood transfusion requirements, although there was
no signiﬁcant difference in time to platelet recovery to
20  109/L [46]. CD34þ cell doses >10  106/kg have been
associated with earlier neutrophil engraftment by 1 to 2 days
and earlier platelet engraftment by 2 to 4 days comparedwith
mid-range cell doses (w3-10  106/kg) [40,44]. One study
found that CD34þ cell doses>15106/kgeliminated theneed
for platelet transfusion support and signiﬁcantly reduced the
duration of thrombocytopenia <50  109/L [47]. The data
supporting the use of higher cell doses arenotwell controlled,
however, and the higher collections attained for these trans-
plants may be a surrogate for less heavily pretreated, lower-
risk patients. More research is needed to determine the
impact of higher cell doses on engraftment kinetics and to
evaluate whether time to collection and stem cell quality, not
simply quantity, may play an important role as well.
Recommendations for stem cell targets and doses
 The minimum recommended stem cell dose is 2  106
CD34þ cells/kg.
 The decision to accept a collection yield of 1-2  106
CD34þ cells/kg for aHSCT should be individualized to
each patient’s clinical parameters and circumstances;
in some cases, the beneﬁt of aHSCT may be sufﬁciently
compelling to use doses in this range if absolutely
necessary.
 Although minimum numbers are clear, the ideal target
numbers are less clear. In general, higher target doses
may result in faster engraftment times, but consider-
ation should be given to the balance between targets
and the number of apheresis sessions required to attain
the target collection. The recommended stem cell
collection target is 3-5  106 CD34þ cells/kg, but in
some cases it may be reasonable to accept a yield of
2.5  106 CD34þ cells/kg in a single apheresis session
rather than prolong the mobilization by several days to
reach a target of 5  106 CD34þ cells/kg.
 CD34þ cell doses of 5  106 cells/kg may lead to
improved platelet recovery and less resource utilization
compared with doses of 3  106 cells/kg, provided
that the higher target can be collected in a few apher-
esis sessions.
 Higher targets are necessary if multiple trans-
plantations are planned. The collection target in this
setting should be double the target used at the indi-
vidual center for a single transplantation, to allow
optimal cell doses for each transplantation [37].
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Various apheresis devices have Food and Drug Adminis-
tration approval for PBSC collection. A review of the advan-
tages and disadvantages of eachmachine is beyond the scope
of this discussion [48-50]. Patients should have vascular ac-
cess evaluated before the start of any apheresis procedure to
determine whether peripheral access is acceptable or if
central venous access is necessary [51]. Stem cell apheresis
can be performed as a standard lower-volume procedure,
with a typical processing volume of 10-15 L, based on 2 to
3 times the patient’s blood volume, as determined by a blood
volume calculation of 70 mL/kg of body weight (ie, a 70-kg
person would have an estimated blood volume of
4900 mL). Larger-volume leukapheresis (LVL) involves pro-
cessing 15-30 L (3 to 6 blood volumes). LVL may be preferred,
because it often results in a net increase in CD34þ cell yield
per apheresis session [52-63], owing to continued mobili-
zation of stem cells from the marrow during the prolonged
apheresis session. Poor mobilizers in particular may have
improved collection with the use of LVL [55,64,65], with
some authors reporting 40%-100% higher stem cell yields in
patients with a preapheresis PB CD34þ count <20 cells/mL
[55,65]. In fact, the high failure rates reported with the
control arms of the Phase III plerixafor trials may be related
in part to the relatively low-volume apheresis mandated by
the study design (3 times blood volume  10%) [66,67].
It should be noted, however, that the processing of large
blood volumes may be associated with increased risks. This
includes exposure to increased amounts of anticoagulant
(sodium citrate in the form of anticoagulant citrate dextrose
solution formula A)whichmay result in decreases in divalent
cations, calcium and magnesium. This in turn may result in
hypocalemic/hypomagnesemic tetany without appropriate
replacement therapy. In addition, LVL can produce coagul-
opathy and possible thrombocytopenia, owing to increased
loss of platelets in the collection bag [61,65,68-70]. Although
numerous studies have been published on the safety, feasi-
bility, and effectiveness of LVL, data from these studies
cannot be compared owing to the lack of uniform mobiliza-
tion and apheresis practice among centers, including mobi-
lization regimens, machine efﬁciency, run variables, blood
volumes processed, duration of the apheresis procedure, and
patient-associated variables, such as initial patient platelet
count. All of these variables will affect the ﬁnal stem cell
collection.
Recommendations for apheresis techniques
 The data regarding apheresis techniques are not stan-
dardized and thus are insufﬁcient for deﬁning a rigid,
universal optimal apheresis strategy.
 Larger processing volumes should be considered in
patients who have mobilized poorly (deﬁned as a PB
CD34þ count <10 to 20 cells/mL) and are reasonable
even with higher PB CD34þ cell counts, because toxic-
ities are generally mild to moderate.
 Rigorous monitoring of electrolyte and coagulation
parameters should be implemented in patients under-
going LVL. RBC and platelet transfusions should be
administered as needed to treat anemia or thrombo-
cytopenia before or after the apheresis procedure;
transfusions should not be administered during the
procedure, which may interfere with the collection
interface. Regardless of volumes used, extending apheresis
beyond 4 days is rarely successful, and remobilization
strategies should be considered in patients who have
not met targets by day 4 of collection.
RECOMMENDATIONS FOR STEM CELL MOBILIZATION
Initial Mobilization Strategies
The primary goal of mobilization is to collect sufﬁcient
stem cells to allow the patient to proceed to aHSCT. Optimal
mobilization not only requires the collection of the targeted
stem cell dose, but also should incorporate strategies to
minimize the number of apheresis sessions required, reduce
costs, and avoid mobilization-related complications, such as
hospitalization for febrile neutropenia. Prevention of mobili-
zation failure should be a top priority, given that failure rates
with traditional strategies arehighas40% [20,71-77] (Table1).
Risk factors for failure include advanced age [78-80], diag-
nosis of NHL [80], previous radiation therapy or extensive
chemotherapy [78,79,81], previous treatment with lenalido-
mide or a purine analog [39,74,77,82-87], previous mobiliza-
tion failure, and low preapheresis circulating PB CD34þ cell
counts (Table 2). Recent data suggest that both diabetes and
smoking may play a role in mobilization failure [88-90].
Can we predict poor mobilizers?
Unfortunately, predicting mobilization failure based on
baseline patient characteristics is highly inaccurate [91],
because even within high-risk groups there will be a subset
of patients who will mobilize sufﬁciently with standard ap-
proaches, and there are patients with no high-risk charac-
teristics who either mobilize poorly or do not mobilize. Thus,
although tailoring mobilization regimens based on upfront
predictivemodels will identify many of those destined to fail,
it is not uniformly predictive, and alternative strategies are
needed.
One strategy for predicting and preventing mobilization
failure is commonly referred to as the “preemptive” (or “just
in time”) approach, which identiﬁes poor mobilizers before
collection based on circulating PB CD34þ counts, based on
the well-established correlation between preapheresis PB
CD34þ cell count and collection yield [92,93]. A recent study
demonstrated a direct linear correlation between PB CD34þ
cell count and overall collection, such that a doubling of the
preapheresis PB CD34þ count doubles the number of CD34þ
cells collected during apheresis [94]. Thus, identiﬁcation of
patients with suboptimal preapheresis PB CD34þ counts may
allow for the salvage of initial mobilization attempts with
novel agents, thereby reducing the high failure rates seen
with traditional strategies. Many centers have developed
algorithms to guide mobilization strategies based on PB
CD34þ cell counts, and this approach has been shown to
improve initial mobilization success rates while efﬁciently
managing resources [95-99].
Steady-state mobilization with growth factors
G-CSF alone as ﬁrst-line mobilization is an attractive op-
tion owing to predictable mobilization kinetics, which in
turn allows for predictable apheresis scheduling and stafﬁng
while decreasing costs of growth factors and the collection
procedure compared with CM. Reported mobilization failure
rates with standard-dose G-CSF (5-16 mg/kg/day) are as high
as 38%, however [20,21,23,39,100-103]. Single-agent G-CSF
has shown some improvement in stem cell yield at higher
doses. up to 40 mg/kg/day [104,105], but with increased
Table 1
Initial Mobilization Failure Rates with Traditional Approaches
Author Patient Population Regimen CD34þ Yield,  106/kg FD Failure Rate, %
Bensinger et al. [39] MM, lymphoma, BC, other n ¼ 124 CM þ G-CSF/GM-CSF 10.75 O 7
n ¼ 119 G-CSF 5.21 5
Pusic et al. [20] MM, lymphoma n ¼ 976 G-CSF 3.36 M 18.6
n ¼ 64 CM þ G-CSF 5.43 18.75
Gertz et al. [73] MM, lymphoma n ¼ 1775 G-CSF  Cy NR O 47
Pavone et al. [72] Lymphoma n ¼ 97 Cy þ G-CSF 28.8 (median for all cohorts) O 17.9
n ¼ 87 DHAP þ G-CSF
n ¼ 83 MAD þ G-CSF
Roberts et al. [75] MM, lymphoma n ¼ 97 CM þ G-CSF NR O 29.9
n ¼ 155 G-CSF NR 38.1
Alegre et al. [21] MM n ¼ 18 Cy þ GM-CSF 6.8 NA NR
n ¼ 22 G-CSF 4.9 NR
Narayanasami et al. [100] Lymphoma n ¼ 22 G-CSF 2.5 M 4.5
n ¼ 24 Cy þ G-CSF 7.2 4.2
Desikan et al. [23] MM n ¼ 22 G-CSF 5.8 O 23
n ¼ 22 Cy þ G-CSF 33.4 18
Dazzi et al. [101] NHL n ¼ 12 G-CSF 2.89 NA NR
n ¼ 12 Cy þ G-CSF 6.41 NR
Schiller [191] MM n ¼ 37 Cy þ G-CSF 4.65 M 0
Pavone et al. [192] NHL n ¼ 38 DHAP þ G-CSF 5.9 O 14.7
n ¼ 34 Cy þ G-CSF 7.1 10.5
Zeller et al. [104] Lymphoma, testicular cancer n ¼ 33 G-CSF 10 mg/kg/d 11.32 NA NR
n ¼ 34 G-CSF 24 mg/kg/d 48.25 NR
Weaver et al. [108] MM, NHL, BC n ¼ 49 CM þ G-CSF 7.1 M 4
n ¼ 49 CM þ GM-CSF 2 8
n ¼ 52 CM þ G-CSF/GM-CSF 5.5 2
Arora et al. [109] MM n ¼ 37 Cy þ GM-CSF 12 NA NR
n ¼ 34 Cy þ G-CSF 16 NR
Demirer et al. [193] MM, lymphoma, BC, other n ¼ 25 CM þ G-CSF 8 mg/kg/d 2.4 NA NR
n ¼ 25 CM þ G-CSF 16 mg/kg/d 7.9 NR
Desikan et al. [24] MM n ¼ 117 G-CSF 6.2 O 26
Gojo et al. [194] MM n ¼ 28 Cy þ G-CSF 21.6 M 14
n ¼ 49 Cy þ VP þ G-CSF 22.5 4
Lefrere et al. [195] MM n ¼ 31 VAD þ G-CSF 7.7 M 10
n ¼ 51 Cy 120 mg/kg þ G-CSF 5.9 4
Stiff et al. [107] Lymphoma (high risk) n ¼ 54 G-CSF 2.4 M 26
n ¼ 48 SCF þ G-CSF 3.6 16
Glaspy et al. [45] BC n ¼ 39 G-CSF 3.2 M 7.6
n ¼ 129 SCF þ G-CSF 7.7 (for SCF doses >10 mg) 1
n ¼ 4 SCF alone 0.2 75
Chao et al. [22] MM, lymphoma n ¼ 143 CM þ G-CSF 18.6 M 4.2
n ¼ 84 G-CSF 7 16.7
Damon et al. [126] MCL n ¼ 69 EAR þ G-CSF 15.9 M 0
Geisler et al. [127] MCL n ¼ 160 DSCM NR M 3
Hiwase et al. [122] MM n ¼ 61 Cy 1-2 g/m2 þ G-CSF 5.1 M 11
n ¼ 26 Cy 3-4 g/m2 þ G-CSF 7.7 8
Sizemore et al. [125] MM n ¼ 37 Cy 2 g/m2 þ G-CSF NR M 13.5
n ¼ 35 Cy 4 g/m2 þ G-CSF NR 3
Sizemore et al. [124] NHL n ¼ 28 Cy 2 g/m2 þ G-CSF NR M 32
n ¼ 28 Cy 4 g/m2 þ G-CSF NR 4
Wood et al. [196] MM n ¼ 152 VP-16 þ G-CSF 12 M 0
Wood et al. [197] Lymphoma n ¼ 159 VP-16 þ G-CSF 6.2 M 6
Bruns et al. [113] MM n ¼ 15 Cy þ PEG 6 mg 10 M 0
n ¼ 15 Cy þ PEG 12 mg 7.4 0
n ¼ 15 Cy þ G-CSF 8.6 0
Zappasodi et al. [114] MM n ¼ 23 DCEP þ PEG 5.7 M 13
Steidl et al. [115] MM n ¼ 12 Cy þ PEG 12 mg 7.4 M 0
Fruehauf et al. [116] MM n ¼ 26 CAD þ PEG 12 mg 9.7 O 12
Isidori et al. [117] Lymphoma n ¼ 25 IEV þ PEG 6 mg 8.7 M 4
Putkonen et al. [118] MM, lymphoma, CLL n ¼ 38 CM þ PEG 6-18 mg 4.9 O 21
Simona et al. [119] Lymphoma n ¼ 38 ESHAP þ PEG 6 mg 9.42 O 17
Russell et al. [76] NHL n ¼ 29 ICE þ PEG 6 mg 4.9 M 31
n ¼ 29 ICE þ PEG 12 mg 4.4 41
n ¼ 32 ICE þ G-CSF 5.1 28
Tricot et al. [120] MM n ¼ 140 DTPACE þ PEG 6 mg  2 14.5 O 11
n ¼ 97 DTPACE þ G-CSF 10 29
Cesaro et al. [121] Pediatric, various diagnoses n ¼ 36 CM þ PEG 8.3 on day 1 Other* 17
n ¼ 36 CM þ G-CSF 8.8 on day 1 8
BC indicates breast cancer; CAD, cyclophosphamide, doxorubicin, and dexamethasone; CLL, chronic lymphocytic leukemia; Cy, cyclophosphamide; DHAP, dexa-
methasone, cisplatin, and cytarabine; DSCM, mobilization off of disease-speciﬁc chemotherapy administered as part of the initial 3-6 cycles; EAR, etoposide,
cytarabine, and rituximab; ESHAP, etoposide, cytarabine, cisplatin, and methylprednisolone; FD, failure deﬁnition; HCVAD, hyperfractionated cyclophosphamide,
vincristine, doxorubicin, and dexamethasone; ICE, ifosfamide, carboplatin, and etoposide; IEV, ifosfamide, epirubicin, and etoposide; M, minimal number of CD34þ
cells required for transplantation; MAD, mitoxantrone, cytarabine, and dexamethasone; MCL, mantle cell lymphoma;MM,multiple myeloma; NR, not reported; O,
optimal number of CD34þ cells required for transplantation; PEG, pegﬁlgrastim; SCF, stem cell factor; VAD, vincristine, doxorubicin, and dexamethasone; DTPACE,
bortezomib, dexamethasone, thalidomide, cisplatin, docorubicin, cyclophosphamide, and etoposide; VP-16, etoposide.
* Inability to attain blood peak of at least 20  106 CD34þ cells/L before leukapheresis.
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Table 2
Risk Factors Associated with Poor Mobilization
Baseline At Time of Mobilization
Treatment-related
 Numerous cycles of
previous chemotherapy
 Previous exposure to melphalan,
ﬂudarabine, platinum-containing
regimens, alkylating agents, or
lenalidomide
 Previous radiation therapy to the
bone marrow
Low steady-state PB
CD34þ cell count
Steady-state
thrombocytopenia
Low preapheresis PB
CD34þ cell count
Low day 1 apheresis yield
Patient-related
 Advanced age
 Diagnosis of NHL
 Diabetes
Bone marrowerelated
 Bone marrow involvement
 Thrombocytopenia
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G-CSF may result in higher CD34þ cell yield [45,107], but this
combination is not available in the United States.
GM-CSF has been shown to be inferior toG-CSF in terms of
number of stem cells collected and in post-transplantation
outcomes of hematopoietic recovery, transfusion and antibi-
otic support, febrile episodes, and hospitalizations [108,109].
It is most often used in remobilization strategies, alone or in
combination with other cytokines or chemotherapy.
Data on the use of pegﬁlgrastim in steady-state mobili-
zation are both limited and mixed. A study of patients with
MM mobilized with a single ﬁxed dose of pegﬁlgrastim
12 mg s.c. demonstrated predictable mobilization kinetics
and similar collection yields and apheresis days compared
with a separate G-CSF cohort [110]. Unfortunately, that study
was limited by its relatively small sample size (19 patients in
the pegﬁlgrastim arm), nonrandomized study design, and
previous therapy restricted to thalidomide, dexamethasone,
and bortezomib. In an unpublished randomized controlled
trial comparing G-CSF 10 mg/kg/day, pegﬁlgrastim 6 mg
single dose, and pegﬁlgrastim 12 mg single dose, conducted
in 2003 and 2004, a total of 38 patients with NHL or Hodgkin
lymphoma completed collection, with only 37% of those
patients collecting at least 2 106 CD34þ cells/kg (54% of the
G-CSF group, 31% of the pegﬁlgrastim 6mg group, and 27% of
the pegﬁlgrastim 12 mg group) [111]. The trial was subse-
quently discontinued early because of futility. However,
another study of patients with MM or NHL undergoing
mobilizationwith either a ﬂat dose of pegﬁlgrastim 12 mg or
G-CSF 10 mg/kg/day demonstrated that pegﬁlgrastim resul-
ted in higher day 4 PB CD34þ cell count (28.7  106 cells/L
versus 18.1  106 CD34þ cells/L) [112]. There are more pub-
lished data supporting the use of pegﬁlgrastim as part of a
CM regimen, with reported failure rates of 0 to 21% and cell
yields and transplantation outcomes comparable to those for
CM þ G-CSF [76,113-121].
CM
CM may be incorporated into the initial induction or
salvage therapy cycles, or may be administered as a stand-
alone cycle apart from standard therapy. The most com-
mon stand-alone regimens include cyclophosphamide at a
range of doses. Higher doses of cyclophosphamide (3-7 g/m2)
are associated with higher cell yields, lower failure rates, and
improved engraftment kinetics [122-125], but also may
result in more toxicity and higher costs.The published literature on the various CM approaches is
vast (Table 1). In general, studies demonstrate that CM will
mobilize more stem cells than G-CSF alone but with a similar
failure rate [20-25], suggesting that CM works best in those
patients already destined to mobilize well. Exceptions to this
rule may exist, however; several recent studies have shown
that CM improves mobilization in traditionally difﬁcult-
to-mobilize patients, such as those with lymphoma
[75,126,127]. In fact, treatment plans for lymphoma that
incorporate mobilization into the initial 3 to 6 cycles of
chemotherapy may reduce failure rates to<3% [126,127]. CM
as a distinct cycle apart from standard chemotherapy may be
a more costly approach than G-CSF alone, however [22].
Furthermore, although CM intuitively would seem to reduce
graft contamination by malignant cells, in practice it has
demonstrated no impact on transplantation outcomes, such
as complete response rate, time to progression, event-free
survival, or overall survival [25,128].
Plerixafor in initial mobilization
Table 3 summarizes the available data on plerixafor-
containing mobilization regimens.
Upfront mobilization
In a phase II trial, the addition of plerixafor to G-CSF
mobilization increased rates of successful mobilization
(deﬁned as 5  106 CD34þ cells/kg) and was associated
with fewer apheresis sessions compared with G-CSF alone
[129]. Two subsequent large Phase III trials of upfront
plerixafor þ G-CSF (P þ G-CSF) mobilization conﬁrmed that
the combination was associated with higher CD34þ cell
yields, better achievement of collection targets, lower failure
rates, and fewer apheresis sessions compared with G-CSF
alone [66,67,130-133].
Those Phase III trials assessed steady-state mobilization
(P þ G-CSF versus placebo þ G-CSF), and did not include a
prospective comparison of P þ G-CSF versus CM þ G-CSF.
Nonetheless, the available nonrandomized data suggest that
PþG-CSF has similar or improved cell yields and failure rates
and improved resource utilization compared with CM alone
[134-136]. A retrospective comparison of patients partici-
pating in the expanded access protocol of P þ G-CSF with
matched historical controls mobilized with CM þ G-CSF
showed 100% successful mobilization in both cohorts with
similar median total CD34þ cells counts collected and similar
mobilization costs in the 2 groups. P þ G-CSF was associated
with reduced resource utilization, more patients completing
apheresis in 1 day, and fewer hospitalizations, transfusions,
and G-CSF doses [134]. Other retrospective analyses have
conﬁrmed that upfront P þ G-CSF has similar or reduced
costs compared with CM þ G-CSF, along with lower failures
rates (6% to 12.5% versus 21% to 29%) [135,136].
Preemptive and risk-adapted plerixafor use
A common trend in mobilization involves the preemptive
addition of plerixafor to steady- state G-CSF in patients
known to mobilize poorly based on preapheresis PB CD34þ
cell counts or to collect poorly based on early daily apheresis
yields. Various institutional approaches have been published
[95-99,131,137]. Costa et al. [95] used center-speciﬁc cost
simulation to develop preestablished PB CD34þ thresholds at
which plerixafor would be added to improve collection ef-
ﬁciency and reduce the cost of mobilization attempts [95].
This resulted in signiﬁcantly lower mobilization failure
rates of 2% to 3% compared with the 22% observed with
Table 3
Initial Mobilization Failure Rates with Plerixafor-containing Approaches
Author Patient Population Regimen CD34þ Yield, 
106/kg
FD Failure
Rate, %
First-line mobilization
DiPersio et al. [66] NHL n ¼ 150 UP þ G-CSF 5.7 O 41/10
n ¼ 148 G-CSF 2 80/45
DiPersio et al. [67] MM n ¼ 148 UP þ G-CSF 13 O 28
n ¼ 154 G-CSF 7.3 66
Shaughnessy et al. [134] MM, NHL n ¼ 33 CM þ G-CSF 11.6 O 0
n ¼ 33 P þ G-CSF 10.7 0
Isola et al. [130] MM n ¼ 25 G-CSF 8.4 NA NA
n ¼ 25 UP 16.1 NA
Campen et al. [136] NHL n ¼ 34 Cy þ G-CSF NR M 29.4
n ¼ 8 UP NR 12.5
Dugan et al. [139] MM, NHL n ¼ 40 UP þ CM þ G-CSF
(various schedules)
NR O 0
Adel et al. [135] MM n ¼ 98 Cy þ G-CSF NR M 21
n ¼ 35 UP NR 6
Risk-adapted
Shapiro et al. [133] High-risk MM, lymphoma n ¼ 124 G-CSF NR M Group 1, 62
Group 2, 79
Group 3, 61
Group 1: 3 þ lines of chemotherapy;
group 2: 4 þ cycles of HCVAD;
group 3: 4 þ cycles of lenalidomide
n ¼ 72 UP NR Group 1, 23
Group 2, 53
Group 3, 0
Li et al. [131] MM, lymphoma n ¼ 23 UP (high-risk patients) 11.7 M 4
Preemptive mobilization
Costa et al. [95] MM, lymphoma n ¼ 34 PEP 6.3 O 3
Costa et al. [138] MM, lymphoma n ¼ 81 CM þ G-CSF 7.74 M 22.2
n ¼ 50 PEP 7 2
Roberts et al. [75] MM, lymphoma n ¼ 155 G-CSF NR O 38
n ¼ 97 CM NR 30
n ¼ 18 UP NR 39
n ¼ 63 PEP NR 24%
Abhyankar et al. [96] MM, lymphoma, other n ¼ 159 PEP 5.8 M 5
Micallef et al. [99] MM, lymphoma, other n ¼ 147 PEP or UP if high risk 5.5 M 5
Micallef et al. [98] MM, lymphoma, other n ¼ 278 G-CSF 5.6 M 19
n ¼ 216 PEP1 6.1 5
n ¼ 98 PEP2 7.8 1
LaPorte et al. [97] MM n ¼ 68 PEP 8.71 M 1
Vishnu et al. [137] MM, NHL n ¼ 46 PEP 4.9 (patients requiring P) M 5
5.9 (patients not requiring P)
Li et al. [131] MM, lymphoma n ¼ 165 PEP þ G-CSF,  CM 6.8 (patients requiring P) M 7
11.7 (patients not requiring P) 0
Awan et al. [149] Various n ¼ 16 CM þ G-CSF þ PEP 3.9 M 0
Varmavuo et al. [151] NHL n ¼ 20 CM þ G-CSF/PEG þ PEP 3.4 M 15
Basak et al. [143] Various n ¼ 48 CM þ G-CSF þ PEP 4.1 M 29
Jantunen et al. [144] MM, NHL n ¼ 16 CM þ G-CSF þ PEP 2.9 M 19
Costa et al. [112] MM, lymphoma n ¼ 74 G-CSF þ PEP 7.26 M 1.3
n ¼ 57 PEG þ PEP 7.54 1.7
FD indicates failure deﬁnition; M, minimal number of CD34þ cells required for transplantation; MM, multiple myeloma; NA, not applicable; NR, not reported; O,
optimal number of CD34þ cells required for transplantation; PEG, pegﬁlgrastim; PEP, preemptive plerixafor; UP, upfront plerixafor.
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of preemptive plerixafor use have shown similar low failure
rates, below 10% [96,97,99,131,137].
Plerixafor also has been used in risk-adapted strategies in
which patients with high-risk baseline characteristics are
mobilized with P þ G-CSF. One single-center report of P þ G-
CSF use in patients at high risk for mobilization failure based
on previous chemotherapy regimens showed signiﬁcantly
improved mobilization compared with historical controls
who received G-CSF alone [133]. Another retrospective study
of P þ G-CSF in patients at high risk for failure based on
medical history found a failure rate of only 4%; however, it
should be noted that one-third of the patients in this cohort
had previously failed mobilization [131].
CM þ P þ G-CSF
Limited data exist on the upfront combination of plerixafor
with CM þ G-CSF (CM þ P þ G-CSF). One small pilot study of
upfront CM þ P þ G-CSF in patients with MM and NHLdemonstrated that the combination is safe and results in a 2-
fold increase in PB CD34þ cell collection; all patients had
successful collection (deﬁned as 2  106 CD34þ cells/kg)
[139]. Another recent study found a success rate of 73% in
patients predicted to be poor mobilizers based on either
baselinecharacteristics orpreviously failedmobilization [140].
More data are available on the use of preemptive plerixafor
to salvage CM þ G-CSF patients who have failed to mobilize
sufﬁcient PB CD34þ cells, or who demonstrate declining PB
CD34þ cell counts during apheresis [32,141-150]. In a small
2-center study, 16 patients received plerixafor salvage after
CMþG-CSF for either a PB CD34þ cell count<10/mL afterWBC
recovery or poor cell yield (<1  106 CD34þ cells/kg) after 2
apheresis sessions [149]. Amean2.4-fold increase inPBCD34þ
cell counts was seen after plerixafor administration, and all
16 patients successfully collected 2  106 CD34þ cells/kg.
Another study of 20 patients with NHL receiving preemptive
plerixafor after poor mobilization with CM showed a success
rate of 85% [151]. Althoughmost of the published literature on
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retrospective analyses or case reports, most demonstrate
successful collection comparable to that in patients who are
good mobilizers [141-147,150]. One study failed to show an
additional beneﬁt with the combination of CM þ P compared
with historical controls [148].
Recommendations for initial mobilization attempts
Prevention of mobilization failure
 The goals of mobilization should be to reduce overall
failure rates to <5%, to minimize mobilization-related
complications, and to optimize resource utilization.
 The use of preapheresis PB CD34þ cell count moni-
toring is recommended to identify poor mobilizers
before failure.
 Preemptive plerixafor use based on PB CD34þ cell count
monitoring, although not evaluated in a Phase III trial,
appears to prevent mobilization failure and may avoid
unnecessary use of plerixafor.
 Upfront steady-state mobilization with P þ G-CSF is a
reliable strategy for preventing remobilization.
 CM þ P þ G-CSF is an emerging mobilization strategy
that merits further evaluation in prospective trials.First-line mobilization strategies
For patients with MM:
 Steady-state mobilization with G-CSF alone in doses
of 10-16 mg/kg/day is an option, but should be limited
to patients with no more than 1 previous line of
therapy, not previously treated with melphalan
or >4 cycles of lenalidomide. In such patients, PB
CD34þ cell count monitoring with preemptive pler-
ixafor will allow for successful collection in the vast
majority of patients.
For patients with NHL:
 Steady-state mobilization with G-CSF alone in doses
of 10-16 mg/kg/day, although associated with higher
failure rates in some patient populations, may be an
option owing to low toxicity and ease of scheduling.
It should be limited to those at low risk for mobili-
zation failure. Again, PB CD34þ count monitoring
with preemptive plerixafor will allow successful
collection in the vast majority of patients.
 CM, either incorporated into the initial 3 to 6 cycles of
planned chemotherapy or as part of a salvage
regimen, is appropriate.
General recommendation for all patients:
 CM versus steady-state cytokine mobilization re-
mains an ongoing debate, but data on head-to-head
comparisons are equivocal. Patient with MM and
patients with NHL respond differently to mobiliza-
tion regimens. Although growth factor alone is
often adequate for patients with early-stage MM, it
is often suboptimal for those with NHL and late-
stage MM. Although success rates are similar to
those seen in steady-state mobilization with G-CSF,
CM as a stand-alone cycle apart from standard
chemotherapy is associated with higher costs and
toxicities.
 Consider limiting stand-alone CM to patients who
have not responded optimally to salvage therapy or
in patients who have failed other strategies. Data to support the use of higher cyclophosphamide
doses (>4 g/m2) are limited, in light of increased
toxicity.
 Upfront plerixafor is a suitable option for all patients,
particularly in the following circumstances: if the goal
is the highest possible CD34þ cell collection yield, if
real-time PB CD34þ cell counts are not available, or if
fewer apheresis days is the top priority. Preemptive
use of plerixafor based on PB-CD34 þmeasurements
is reasonable in other cases.
 Firm recommendations regarding the use of CM
versus P þ G-CSF cannot be made owing to a lack of
data; controlled prospective trials comparing the 2
strategies should be considered.Impact of Novel Therapies on Stem Cell Mobilization
Lenalidomide is an effective and commonly used agent for
induction in patients with MM, but has consistently shown a
negative impact on stem cell collection [74,77,83-85,152].
This effect may be linked to the duration of lenalidomide
exposure, given that stem cell yields may be signiﬁcantly
lower in patients receiving more than 4 to 6 cycles
[74,84,152]. Both CM and plerixafor-containing mobilization
strategies have been shown to overcome this negative effect
and result in successful collections [133,152-156].
Most studies of bortezomib-containing induction regi-
mens have shown no signiﬁcant impact on total stem cell
yield or failure rates [157-162], although a review of Inter-
national Myeloma Foundation 2005-01 trial data has
revealed trends toward reduced overall collections and
slightly higher failure rates [163]. Bendamustine is an even
more recent addition to the treatment arsenal for both
lymphoid malignancies and MM, and information on the its
ability to mobilize stem cells after exposure is limited. There
are some data suggesting the feasibility of stem cell collec-
tion in patients with NHL or MM previously treated with
bendamustine [164-166]. Fludarabine is often used in the
treatment of hematologic malignancies, and has been shown
to impair collection of PB CD34þ cells [86,87], particularly at
lifetime cumulative doses >150 mg/m2 [87].
Recommendations for mobilization after treatment with
novel agents or agents known to inhibit stem cell collection
 Early collection (between the second and fourth cycles of
lenalidomide) should be performed whenever possible.
 Most experts recommend a washout period of 2 to
4 weeks between the last lenalidomide dose and the
start of apheresis.
 There are insufﬁcient data on which to recommend a
single mobilization strategy in patients with lenalido-
mide exposure, but PþG-CSF and CM have been shown
to be effective approaches.
 Mobilizationwith G-CSF alone is insufﬁcient in patients
with extensive (>4 to 6 cycles) lenalidomide pretreat-
ment and should be avoided.
Remobilization Options
Cytokine-only strategies are inadequate for remobiliza-
tion attempts. One study has shown that the combination of
growth factors is less costly and equally as effective as high-
dose G-CSF in remobilization [167], but these strategies are
still associated with an 82% failure rate [20]. CM historically
has been recommended as the primary remobilization op-
tion in patients failing G-CSF alone [168]. Unfortunately, the
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The remaining traditional option for those previously failing
mobilization is bone marrow harvest; however, this
approach is associated with increased costs and reduced
quality of life [102,169,170]. Furthermore, this approach is
rarely successful in the event of failed PBSC collection.
Of the currently available remobilization options, steady-
state mobilization with P þ G-CSF is associated with the
lowest failure rates, below30% [20,171,172]. The single-center
series that reported remobilization failure ratesof 82%withG-
CSF and 74% with CM found a failure rate of only 28% with
P þ G-CSF [20]. Data on the use of plerixafor in combination
with CM for remobilization are limited and insufﬁcient for
drawing any conclusions regarding its utility [173]; this may
be a promising strategy, but appropriate timing of plerixafor
administration remains to be determined, owing to the vari-
able mobilization kinetics with CM regimens.
Recommendations for remobilization
 Cytokine-alone strategies should not be used for
remobilization.
 Plerixafor should be included in the remobilization
regimen for patients failing a noneplerixafor-contain-
ing mobilization attempt, and also may be effective in
patients who have failed previous plerixafor-based
mobilization [174]. Remobilization options include
P þ G-CSF and CM þ G-CSF þ P.
 The addition of plerixafor to CM for remobilization
should be explored in prospective trials.
 CM is an acceptable remobilization strategy for patients
who have failed cytokine-only mobilization.
 Bone marrow harvest should be reserved as a third-line
approach in patients ineligible for mobilization clinicalTable 4
Algorithms for Preemptive Plerixafor Use in Stem Cell Mobilization
Study Target CD34þ Cell Yield,
cells/kg
Criteria for Plerixafor Adm
Costa et al. [95] 6  106 (some MM) Preestablished PB CD34þ t
cost simulation, for examp
target of 3  106/kg, and t
target of 6  106/kg
3  106 (all others)
Costa et al. [138] 6  106 (some MM) Preestablished PB CD34þ t
cost simulation, for examp
target of 3  106/kg, and t
target of 6  106/kg
3  106 (all others)
Abhyankar et al. [96] 2.5  106 (single) Day 5 PB CD34þ <10 cells
apheresis on day 6
Day 5 PB CD34þ 10 but <
2.5, begin apheresis witho
apheresis but administer P
Day 5 PB CD34þ 20 cells
without P
Apheresis day 1 cell yield
collection: Administer P
5  106 (tandem)
Micallef et al. [99] 2  106 (minimum) Day 5 PB CD34þ <10 cells
yield of <0.5  106/kg
Micallef et al. [98] 2  106 (minimum) PEP1: Same as above
PEP2: Day 4 PB CD34þ <10
(tandem) or apheresis day
any subsequent daily yield
LaPorte et al. [97] 4  106 (target) Day 4 PB CD34þ <12 cells
yield of <1  106 or 50%2  106 (minimum)
Devine (unpublished data) 4  106 (MM) Day 4 PB CD34þ<7 cells/mL
<10/L, give P, begin apher
yield <50% target collectio
2  106 (others)
FD indicates failure deﬁnition; FN, febrile neutropenia; M, minimal number of CD
number of CD34þ cells required for transplantation; P, plerixafor; PEP, preemptivetrials and in whom the beneﬁt of aHSCT is sufﬁciently
compelling to outweigh the potential drawbacks.
Mobilization Algorithms to Optimize Mobilization
Outcomes
Given the currentmobilization options and thedifferences
in failure rates, costs, resource utilization, and clinical
outcomes among these options, numerous investigators have
performed pharmacoeconomic analyses to identify the
most cost-effective mobilization strategies [75,130-
132,134,136,137,175,176]. Their ﬁndings may have limited
application to other institutions, however, given the differing
costs, patient populations, transplantation goals, and mobi-
lization strategies among centers. Without pharmacoeco-
nomic data from a multicenter controlled trial, centers have
developed algorithms to guide the use of plerixafor within
steady-state G-CSF mobilization based on PB CD34þ cell
counts, daily apheresis yields, and the presence of risk factors
for failure [96,98,99,133,138]. In these algorithms, the most
common approach requires performing PB CD34þ cell anal-
ysis on day 4 of G-CSF administration; if the count is below a
predetermined threshold, then plerixafor is administered
on the evening of day 4, and the start of apheresis is delayed
until day 5. Many algorithms also incorporate criteria for
optimal daily apheresis yields, and allow for the addition of
plerixafor if a daily collection is suboptimal. The use of these
algorithms has reduced mobilization failure rates to below
10% (Table 4).
Recommendations for algorithm development
 Each center should develop and implement its own
algorithms for applying various mobilization strategies,
with the goal of optimizing collection yields.inistration Regimen FD Failure
Rate, %
hreshold derived from
le, threshold of 14 for a
hreshold of 25 for a
n ¼ 34 PEP (n ¼ 11 G-CSF alone,
n ¼ 23 P þ G-CSF)
O 3
hreshold derived from
le, threshold of 14 for a
hreshold of 25 for a
n ¼ 50 PEP M 2
n ¼ 81 CM þ G-CSF 22
/mL: Administer P, begin
20 cells/mL: If target is
ut P; if target is 5, begin
that night
/mL: Begin apheresis
<50% of desired
n ¼ 159 PEP (n ¼ 104 G-CSF alone,
n ¼ 55 P þ G-CSF)
M 5
/mL or daily apheresis n ¼ 147 UP for high risk, PEP for
all others
M 5
(single) or <20 cells/mL
1 yield <1.5  106/kg or
<0.5  106/kg
n ¼ 278 G-CSF alone M 19
n ¼ 216 PEP1 þ G-CSF 5
n ¼ 98 PEP2 þ G-CSF 1
/mm3 or daily apheresis
of previous day’s yield
n ¼ 68 PEP (n ¼ 38 G-CSF alone,
n ¼ 30 P þ G-CSF)
M 1
, give P; day 5 PB CD34þ
esis on day 6 or day 1
n
PEP U 6
34þ cells required for transplantation; MM, multiple myeloma; O, optimal
plerixafor; U, unknown; UP, upfront plerixafor.
Tab
Pub
A
S
A
W
D
D
BC
CD3
opt
fact
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regarding priorities of the transplantation center (eg,
highest possible cell yield versus fewest apheresis
days), priorities of patients and caregivers (eg, reduced
hospitalizations, fewer days missed from work, less
time spent in/around the transplantation and collection
center), relationship of PB CD34þ cell count to collec-
tion yield in the center, center-speciﬁc cost assess-
ments, and minimum and target cell collections.FUTURE DIRECTIONS
Novel mobilization regimens have changed the climate of
stem cell transplantation such aHSCTmay now be performed
in more than 90% of those patients in whom the procedure is
indicated, with a minimal need for remobilization strategies.
The precise regimen that is most effective remains to be
determined, however, and may vary depending on patient
population and the speciﬁc goal of stem cell collection.
Extensive Phase III clinical trial data on mobilization ap-
proaches are lacking (Table 5) [13], and further prospective
studies are needed to answer important questions regarding
ﬁrst-line and secondary mobilization strategies.
The effect of mobilization strategy, particularly mobili-
zation strategies containing plerixafor, on tumor cell mobi-
lization remains unknown and should be explored in future
trials. Plerixafor is known to displace acute leukemia cells
from their microenvironment into the PB (reviewed in [177]),
a phenomenon that has been therapeutically explored as a
chemotherapy sensitization strategy [178-180]. Similarly,
cancer cell mobilization with plerixafor has been detected in
patients with MM in some [181], but not all [182,183],
studies. Mobilization of cancer cells also occurs with growth
factor alone [184,185] and with chemotherapy plus growth
factor [184,186]. It is unknown whether the mobilization ofle 5
lished Phase III Mobilization Data
uthor Patient
Population
Regimen CD34þ
Yield,  106/
kg
FD Failure
Rate, %
hpall et al.
[198]
BC n ¼ 100,
SCF þ G-CSF
5.3 O 37
n ¼ 103,
G-CSF
4.8 53
ndré et al.
[199]
BC, MM,
lymphoma
n ¼ 66,
G-CSF 5
mg/kg
7.2 M 7
n ¼ 62,
G-CSF 10
mg/kg
12.0 7
eaver et al.
[200]
BC, MM,
lymphoma
n ¼ 51,
CM þ G-CSF
12 O 12
n ¼ 52, CM þ
GM-CSF
5.4 47
n ¼ 53, CM þ
G-CSF þ
GM-CSF
10.5 19
iPersio et al.
[66]
NHL n ¼ 150,
UP þ G-CSF
5.7 O 41/10
n ¼ 148,
G-CSF
2 80/45
iPersio et al.
[67]
MM n ¼ 148,
UP þ G-CSF
13 O 28
n ¼ 154,
G-CSF
7.3 66
indicates breast cancer; FD, failure deﬁnition; M, minimal number of
4þ cells required for transplantation; MM, multiple myeloma; O,
imal number of CD34þ cells required for transplantation; SCF, stem cell
or; UP, upfront plerixafor.MMor NHL cells to the PBwill differ in different mobilization
strategies, or whether the contamination of apheresis
products with tumor cells will have any inﬂuence on the
frequency or timing of relapse [187].
Investigations of both clinical effectiveness and cost-
effectiveness are needed for CM versus steady-state mobili-
zation with P þ G-CSF, for preemptive plerixafor versus
upfront plerixafor, and for the role of CMþ G-CSFþ P in ﬁrst-
line and secondary mobilization. Pharmacoeconomics and
cost endpoints should be incorporated into all future pler-
ixafor trials, and are warranted for existing trial data.
The bone marrow microenvironment and stem cell traf-
ﬁcking mechanisms also merit further study. Interestingly,
when plerixafor is added to stromal cells, CXCR4 expression
increases owing to blockade of SDF-1emediated CXCR4
internalization,with theeffectof sendinga “survival signal” to
the mobilized stem cells to return to the marrow [188]. In
contrast, G-CSF down-regulates CXCR4 and SDF-1, potentially
blocking the rehoming process and resulting in persistent
mobilization of hematopoietic stem cells. Manipulation of
this rehoming signal has ramiﬁcations both for increasing or
prolonging stem cell mobilization, as well as improving the
efﬁciency of engraftment post-transplantation. Various other
chemokines that may be useful in the mobilization of stem
cells are in early stages of investigation [189], including the
small-molecule inhibitor of VLA-4, BIO5192, which in mouse
models has demonstrated additive mobilization effects in
combinationwith plerixafor [190]. These investigations likely
will result in the introduction of additional chemokine mol-
ecules to the mobilization arsenal, requiring continuing
reassessment of mobilization standards.ACKNOWLEDGMENTS
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